Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 12/20 | 0.40 |
| ▸ | IDO1 | P14902 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6124262 | 0.82 | IDO1 (0.49) | CREBBPIDO1KCNH2CYP3A4CYP2C9 | |
| SCHEMBL7941087 | 0.74 | NOTUM (0.51) | KDM4ECYP11B2 | |
| SCHEMBL4774603 | 0.73 | IDO1 (0.44) | IDO1KCNH2KDM4ECYP3A4CYP2C9 | |
| SCHEMBL10280588 | 0.71 | CYP11B1 (0.45) | KDM4ECYP11B2CYP2C9 | |
| SCHEMBL25029074 | 0.70 | CREBBP (0.36) | CREBBPIDO1KCNH2CYP11B2BRD4 | |
| SCHEMBL9799093 | 0.70 | NOTUM (0.69) | MEN1KMT2A | |
| SCHEMBL30204132 | 0.70 | NOTUM (0.69) | MEN1KMT2A | |
| SCHEMBL19864622 | 0.68 | JAK2 (0.34) | IDO1KCNH2CYP3A4CYP2C9 | |
| SCHEMBL19864633 | 0.68 | CYP2D6 (0.38) | IDO1KCNH2MEN1KMT2ACYP3A4 | |
| SCHEMBL29173113 | 0.68 | KDM1A (0.43) | IDO1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809318-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8487099-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-05-24 | — | — | US | disclosed |
| US-20120107328-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2012-05-03 | — | — | US | disclosed |
| US-20110306593-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME LLC | 2011-12-15 | — | — | US | disclosed |
| US-20110263529-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107328-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | CREBBP 657/4885IDO1 4504/4885KCNH2 4241/4885 |
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | CREBBP 554/4885IDO1 4402/4885KCNH2 4062/4885 |
| US-20110306593-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | CREBBP 531/4885IDO1 3823/4885KCNH2 4131/4885 |
| US-20110263529-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | CREBBP 508/4885IDO1 4405/4885KCNH2 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.